Please visit answersincme.com/SWS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver cancer discusses emerging transarterial chemoembolization (TACE) plus immunotherapy–based combinations in intermediate-stage hepatocellular carcinoma (iHCC). Upon completion of this activity, participants should be better able to: Identify the limitations of currently available therapeutic approaches for patients with locoregional therapy–eligible, unresectable hepatocellular carcinoma (HCC); Describe the clinical significance of combination therapies that involve transarterial chemoembolization (TACE) and immunotherapy for patients with intermediate HCC (iHCC); and Review clinical strategies to integrate TACE plus immunotherapy–based combination regimens into the treatment paradigm for patients with iHCC, based on the preliminary data.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related